ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,381 to 2,400 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Standard Practice vs Personal Hand Hygiene Device: deaths from any cause6 of 1,620

7 of 1,636

-0.1 points

-0.6 to 0.4

3,256NCT02252562

Hand Hygiene and Hospital Acquired Infections

Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause48 of 1,622

61 of 1,628

-0.8 points

-2.0 to 0.5

3,250NCT01275677

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events31 of 1,615

96 of 1,625

-4.0 points

-5.4 to -2.7

3,240NCT01275677

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Clodronate vs Placebo: deaths from any cause5 of 1,612

12 of 1,623

-0.4 points

-1.0 to 0.1

3,235NCT00009945

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

Clodronate vs Placebo: serious adverse events340 of 1,612

350 of 1,623

-0.5 points

-3.3 to 2.4

3,235NCT00009945

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: 12-month Composite Major Adverse Cardiac Event (MACE)421 of 2,439

140 of 787

-0.5 points

-3.7 to 2.4

3,226NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 21,487 of 1,614

1,486 of 1,610

-0.2 points

-2.0 to 1.7

3,224NCT03164564

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: Number of Pariicipants With Documented Incident HIV Infections4 of 1,614

36 of 1,610

-2.0 points

-2.8 to -1.3

3,224NCT03164564

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: deaths from any cause3 of 1,614

0 of 1,610

0.2 points

-0.1 to 0.5

3,224NCT03164564

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: serious adverse events33 of 1,614

33 of 1,610

-0.0 points

-1.0 to 1.0

3,224NCT03164564

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Dronedarone vs Placebo: serious adverse events113 of 1,614

77 of 1,609

2.2 points

0.6 to 3.9

3,223NCT01151137

Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy

qHPV in Base Study vs Placebo in Base Study: Number of Participants With Vaccine-Related SAEs After Vaccine Administration0 of 1,890

1 of 1,327

-0.1 points

-0.4 to 0.1

3,217NCT00090220

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

qHPV in Base Study: All Participants vs Base Study: Placebo: Number of Participants With an SAE Resulting in Death After Vaccine Administration8 of 1,890

4 of 1,327

0.1 points

-0.4 to 0.6

3,217NCT00090220

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: All Cause Mortality at 12 Months56 of 2,424

19 of 785

-0.1 points

-1.5 to 1.0

3,209NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Do-not-resuscitate Order1,336 of 1,519

1,504 of 1,687

-1.2 points

-3.4 to 1.0

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Palliative Care Consult Order1,208 of 1,519

1,426 of 1,687

-5.0 points

-7.7 to -2.3

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Intravenous Line141 of 1,519

184 of 1,687

-1.6 points

-3.7 to 0.5

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Nasogastric Tube161 of 1,519

141 of 1,687

2.2 points

0.2 to 4.3

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Basic Implementation Approach vs Enhanced Implementation Approach: Location of Death436 of 1,519

408 of 1,687

4.5 points

1.5 to 7.6

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Pastoral Care Visit1,060 of 1,519

1,271 of 1,687

-5.6 points

-8.6 to -2.5

3,206NCT02383173

Evaluation of Methods for Implementation of a Comfort Care Order Set

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=120"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=120

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02252562-deaths",
        "title": "Standard Practice vs Personal Hand Hygiene Device: deaths from any cause",
        "summary": "6 of 1620 against 7 of 1636; risk difference -0.1 points, 95% interval -0.6 to 0.4; NCT02252562, Hand Hygiene and Hospital Acquired Infections",
        "record": "/library/comparisons/NCT02252562-deaths",
        "nct_id": "NCT02252562",
        "kind": "deaths",
        "participants": 3256,
        "risk_difference": {
          "value": -0.0005750249026532641,
          "lower": -0.005526341145047975,
          "upper": 0.004304692530978662
        },
        "group_1": "6 of 1,620",
        "group_2": "7 of 1,636",
        "difference": "-0.1 points",
        "interval": "-0.6 to 0.4",
        "trial_title": "Hand Hygiene and Hospital Acquired Infections"
      },
      {
        "id": "NCT01275677-deaths",
        "title": "Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause",
        "summary": "48 of 1622 against 61 of 1628; risk difference -0.8 points, 95% interval -2.0 to 0.5; NCT01275677, Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer",
        "record": "/library/comparisons/NCT01275677-deaths",
        "nct_id": "NCT01275677",
        "kind": "deaths",
        "participants": 3250,
        "risk_difference": {
          "value": -0.00787619252477452,
          "lower": -0.02049847589553446,
          "upper": 0.004608420228512126
        },
        "group_1": "48 of 1,622",
        "group_2": "61 of 1,628",
        "difference": "-0.8 points",
        "interval": "-2.0 to 0.5",
        "trial_title": "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=121",
  "request_id": "dG4gvF57MQwxtQ2w"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?